Volume 5, Number 1 (January 2007)

Bench to Bedside

9

  

Pharmacogenomics of Cancer Chemotherapy-Induced Toxicity
C. Ryan Miller, MD, PhD, and Howard L. McLeod, PharmD

Department of Pathology and Immunology and Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, and UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill

abstract full text 156 kb

 

PEER VIEWPOINT
Challenges in the Development and Use of Pharmacogenomic Markers in Oncology
Federico Innocenti, MD, PhD, Department of Medicine, Cancer Research Center, University of Chicago, Chicago, Illinois

full text 57 kb

19

  

Role of Chemotherapy for Palliation in the Lung Cancer Patient
Shannon Stinnett, MD, Laura Williams, MD, and David H. Johnson, MD

Division of Hematology & Oncology, Vanderbilt University School of Medicine, and Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

abstract full text 172 kb

 

PEER VIEWPOINTS
Palliative Chemotherapy for Non-Small Cell Lung Cancer: A Measured Dose of Reality
Gregory P. Kalemkerian, MD, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor

full text 61 kb

 

Complexities of Quality of Life Analysis in Non-Small Cell Lung Cancer
Jennifer Temel, MD, Harvard Medical School, Boston, Massachusetts

full text 57 kb

Original Research

36

  

Communicating About Chemotherapy-Induced Anemia
Brad Davidson, PhD, Diane Blum, MSW, David Cella, PhD, Heidi Hamilton, PhD, Lillian Nail, PhD, RN, FAAN, and Roger Waltzman, MD

MBS/Vox, Parsippany, New Jersey; CancerCare, Inc., New York, New York; Northwestern University Feinberg School of Medicine and Center on Outcomes, Research, and Education, Evanston Northwestern Healthcare, Evanston, Illinois; Georgetown University, Washington, DC; Oregon Health and Sciences University, Portland; and Saint Vincent’s Hospital, New York, New York

abstract full text 114 kb

41

  

Interleukin-1 Genetic Polymorphisms and Their Relationship to the Cancer Anorexia/Weight Loss Syndrome in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Aminah Jatoi, MD, Phuong L. Nguyen, MD, Nathan Foster, MS, David Sun, PhD, Philip J. Stella, MD, Megan Campbell, MS, Loren K. Tschetter, MD, Shaker R. Dakhil, MD, FACP, James A. Mailliard, MD, and Daniel A. Nikcevich, MD, PhD

Mayo Clinic and Mayo Foundation, Rochester, Minnesota; Michigan Cancer Consortium and St. Joseph Mercy Hospital Cancer Center, Ann Arbor; Sioux Community Cancer Consortium, Sioux Falls, South Dakota; University of Kansas School of Medicine and Wichita Community Clinical Oncology Program, Wichita, Kansas; Creighton University School of Medicine and Missouri Valley Cancer Consortium, Omaha, Nebraska; and Duluth Community Clinical Oncology Program, Duluth, Minnesota

abstract full text 156 kb

How We Do It

48

  

Enhancing Participation in Clinical Research: Keys to Obtaining Informed Consent
David Green, MD, PhD, and Frederick R. Rickles, MD

Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, and Departments of Medicine and Pediatrics and the Department of Pharmacology and Physiology, The George Washington University School of Medicine and Health Sciences and the Children’s National Medical Center, Washington, DC

full text 74 kb

© 2007 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.